Home Cart Sign in  
Chemical Structure| 2222635-15-4 Chemical Structure| 2222635-15-4

Structure of DCLK1-IN-1
CAS No.: 2222635-15-4

Chemical Structure| 2222635-15-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DCLK1-IN-1 is a selective, in vivo-compatible chemical probe targeting the kinase domain of dual-specificity tyrosine-regulated kinase-like 1 (DCLK1). It inhibits both DCLK1 and DCLK2 kinases, with IC50 values of 9.5/57.2 nM (DCLK1) and 31/103 nM (DCLK2), and is useful for studying DCLK1's biological characteristics and its role in tumors like DCLK1+ pancreatic ductal adenocarcinoma (PDAC).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DCLK1-IN-1

CAS No. :2222635-15-4
Formula : C26H28F3N7O2
M.W : 527.54
SMILES Code : O=C1N(CC(F)(F)F)C2=CN=C(NC3=CC=C(N4CCN(C)CC4)C=C3OC)N=C2N(C)C5=CC=CC=C15
MDL No. :MFCD32671365
InChI Key :OQFCHSFVWSLDAO-UHFFFAOYSA-N
Pubchem ID :134457640

Safety of DCLK1-IN-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
DLD-1 cells 1 μM 24 h Evaluate the effect of DCLK1-IN-1 on DLD-1 cell proliferation, invasion, and spheroid formation, showing significant inhibition of these processes Cell Chem Biol. 2020 Oct 15;27(10):1229-1240. e4
DCLK1-FL1Δ (residues 50-686) 20 μM and 40 μM Confirm the binding of DCLK1-IN-1 to the DCLK1 long isoform Commun Biol. 2021 Sep 20;4(1):1105
Panc-1 cells 5 μM, 10 μM 48 h DCLK1-IN-1 effectively blocks EMT process and restores T-cell activity Transl Oncol. 2022 Mar;17:101317
Huh7 cells 5 μM 48 h DCLK1-IN-1 inhibited DCLK1 kinase activity, reducing the production of SARS-CoV-2 viral particles and inflammatory cytokine secretion. J Virol. 2022 Sep 14;96(17):e0096722
Calu3 cells 5 μM and 10 μM 48 h Inhibition of DCLK1 kinase activity reduced the production of SARS-CoV-2 viral proteins (nucleocapsid and Spike) and decreased the infectivity of viral particles. J Virol. 2022 Sep 14;96(17):e0096722
Calu-3 cells 5.0 µM 48 h DCLK1-IN-1 inhibits DCLK1 kinase activity, effectively blocking SARS-CoV-2 replication-transcription processes and reversing virus-induced dysregulation of cell signaling pathways. J Virol. 2023 Nov 30;97(11):e0119423
HCT116 279 nM 2 h Evaluate the target engagement of DCLK1-IN-1 in HCT116 cells, showing potent binding to DCLK1. Nat Chem Biol. 2020 Jun;16(6):635-643
PATU-8902 2.5 μM 24 h Evaluate the effect of DCLK1-IN-1 on PATU-8902 cells, showing minimal effects on cell viability and gene expression. Nat Chem Biol. 2020 Jun;16(6):635-643
PATU-8988T 2.5 μM 24 h Evaluate the effect of DCLK1-IN-1 on PATU-8988T cells, showing minimal effects on cell viability and gene expression. Nat Chem Biol. 2020 Jun;16(6):635-643

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
K18-hACE2 transgenic mice SARS-CoV-2 infection model Intraperitoneal injection 10 mg/kg Once daily for 4 days DCLK1-IN-1 significantly reduced viral RNA levels, downregulated inflammatory cytokines, restored normal cell signaling pathways, and improved lung pathology. J Virol. 2023 Nov 30;97(11):e0119423
Nude mice Ovarian cancer peritoneal metastasis model Intraperitoneal injection 25 mg/kg Every other day for 30 days To evaluate the in vivo efficacy of combining DCLK1-IN-1 with cisplatin, showing significant reduction in tumor growth and peritoneal metastases. Cancer Lett. 2023 Dec 1;578:216437
Mice Swiss albino mice Intravenous and oral 2 mg/kg (IV), 10 mg/kg (PO) Single dose, 24-hour observation Evaluate the pharmacokinetic properties of DCLK1-IN-1 in mice, showing a half-life of 2.09 h and 81% oral bioavailability. Nat Chem Biol. 2020 Jun;16(6):635-643

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.48mL

1.90mL

0.95mL

18.96mL

3.79mL

1.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories